Novo Nordisk (NYSE: NVO) announced FDA approval for Awiqli (insulin icodec), becoming the world’s first and currently only once-weekly long-acting basal insulin for improving glycemic control in adults with type 2 diabetes (T2D) as an adjunct to diet and exercise. The approval, based on the ONWARDS Phase IIIa program demonstrating non-inferior A1C reduction vs. daily basal insulin, follows earlier approvals in China (May 2024), EU, Canada, Australia, Japan, and Switzerland, though the FDA rejected the type 1 diabetes indication in July 2024.
Regulatory Milestone
Item
Detail
Agency
U.S. Food and Drug Administration (FDA)
Approval Type
Marketing authorization
Product
Awiqli (insulin icodec)
Developer
Novo Nordisk (NYSE: NVO)
Indication
Type 2 diabetes only – glycemic control adjunct to diet/exercise
Dosing
Once-weekly – first and only long-acting basal insulin with weekly frequency
No new safety signals; hypoglycemia rates comparable
Strategic Context & Market Impact
Factor
Implication
Basal Insulin Market
$10+ billion globally; dominated by glargine (Lantus), detemir (Levemir), degludec (Tresiba) – all daily dosing; Awiqli’s weekly convenience disrupts standard of care
Adherence Advantage
~300 fewer injections annually vs. daily basal; addresses “injection fatigue” and treatment discontinuation – major unmet need in T2D management
Type 1 Diabetes Limitation
FDA rejection July 2024 – restricts label to T2D only; T1D opportunity lost vs. EU/China approvals; may require additional cardiovascular outcomes data
Expected premium to daily basal insulins (~20–30%) – justified by convenience and adherence benefits; formulary negotiations critical for U.S. access
Commercial Timeline: U.S. launch Q2 2026; Medicare/Medicaid coverage determination 2026–2027; potential 20–25% share of new basal insulin prescriptions by 2028
Global Sales Forecast: Peak sales $3–5 billion annually (T2D only); would have been $5–7 billion with T1D approval
Forward‑Looking Statements This brief contains forward‑looking statements regarding U.S. commercial launch execution, formulary placement, and potential type 1 diabetes resubmission. Actual results may differ due to competitive dynamics with daily basal insulins, reimbursement negotiations, and long-term cardiovascular safety surveillance requirements.-Fineline Info & Tech
By Fineline Cube 